Annis Gardner Whiting Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-119
Closed -$66.9K – 766
2026
Q1
$66.9K Buy
119
+21
+21% +$13.5K 0.01% 527
2025
Q4
$66.3K Buy
98
+14
+17% +$9.53K 0.01% 482
2025
Q3
$53.7K Sell
84
-5
-6% -$3.04K 0.01% 490
2025
Q2
$47.7K Buy
+89
New +$42.6K 0.02% 429
2025
Q1
– Sell
-6
Closed -$2.48K – 787
2024
Q4
$2.48K Hold
6
– – ﹤0.01% 673
2024
Q3
$3.03K Sell
6
-63
-91% -$30.6K ﹤0.01% 677
2024
Q2
$33.6K Sell
69
-20
-22% -$10K 0.01% 471
2024
Q1
$48.1K Buy
89
+61
+218% +$33.3K 0.02% 386
2023
Q4
$15.5K Buy
28
+23
+460% +$10.8K 0.01% 434
2023
Q3
$2.19K Buy
+5
New +$2.49K ﹤0.01% 609

Other funds holding IDXX

Annis Gardner Whiting Capital Advisors's IDXX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 119 shares — an estimated $66.9K sold.

Annis Gardner Whiting Capital Advisors first reported a position in IDXX in Q3 2023 and held it in 10 quarters. The position peaked at $66.9K in Q1 2026. 1,306 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 119 Idexx Laboratories shares in Q2 2026, an estimated $66.9K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Idexx Laboratories in Q3 2023 and held it in 10 quarters.
  • Annis Gardner Whiting Capital Advisors's Idexx Laboratories position peaked at $66.9K in Q1 2026.
  • 1,306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.